Alpha 2.0
Login Register
» Authors » T Cascone

T Cascone

Explore the profile of T Cascone including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 313
Followers 0
Related Specialties
Oncology
Molecular Biology
Top 10 Co-Authors
J V Heymach
F Ciardiello
F Morgillo
M P Morelli
M Orditura
T Troiani
A Weissferdt
J Wu
B Sepesi
J Zhang
Published In
Ann Oncol
Oncogene
Br J Cancer
Cancer Invest
ESMO Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer
Tran H, Heeke S, Sujit S, Vokes N, Zhang J, Aminu M, et al.
Ann Oncol . 2023 Nov; 35(2):183-189. PMID: 37992871
Background: Predicting relapse and overall survival (OS) in early-stage non-small-cell lung cancer (NSCLC) patients remains challenging. Therefore, we hypothesized that detection of circulating tumor DNA (ctDNA) can identify patients with...
2.
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer
Federico L, McGrail D, Bentebibel S, Haymaker C, Ravelli A, Forget M, et al.
Ann Oncol . 2021 Oct; 33(1):42-56. PMID: 34653632
Background: Despite the importance of tumor-infiltrating T lymphocytes (TILs) in cancer biology, the relationship between TIL phenotypes and their prognostic relevance for localized non-small-cell lung cancer (NSCLC) has not been...
3.
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
Cascone T, Sacks R, Subbiah I, Drobnitzky N, Piha-Paul S, Hong D, et al.
ESMO Open . 2021 Mar; 6(2):100079. PMID: 33721621
Background: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR),...
4.
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer
Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers L, Cascone T, et al.
Ann Oncol . 2021 Feb; 32(6):817-819. PMID: 33617938
No abstract available.
5.
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
Morgillo F, Cascone T, DAiuto E, Martinelli E, Troiani T, Saintigny P, et al.
Br J Cancer . 2011 Jul; 105(3):382-92. PMID: 21750552
Background: To study the molecular mechanisms regulating cancer cell resistance to four different tyrosine kinase inhibitors (TKIs): erlotinib, gefitinib, vandetanib and sorafenib. Methods: An in vitro model of acquired resistance...
6.
Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors
Nilsson M, Zage P, Zeng L, Xu L, Cascone T, Wu H, et al.
Oncogene . 2010 Mar; 29(20):2938-49. PMID: 20208561
Novel treatment approaches are needed for children with advanced neuroblastoma. Studies with neuroblastoma cells have indicated the presence of a hypoxia-driven vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-1 autocrine loop...
7.
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells
Xu L, Nilsson M, Saintigny P, Cascone T, Herynk M, Du Z, et al.
Oncogene . 2010 Feb; 29(18):2616-27. PMID: 20154724
Recent studies have established that amplification of the MET proto-oncogene can cause resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) cell...
8.
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer
Iovino F, Ferraraccio F, Orditura M, Antoniol G, Morgillo F, Cascone T, et al.
Cancer Invest . 2008 Mar; 26(3):250-5. PMID: 18317965
Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis, associated with unfavorable clinical characteristics in breast cancer. The aim of this study was to evaluate different angiogenic markers...
9.
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy
Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, et al.
Ann Oncol . 2006 Jun; 17 Suppl 7:vii109-14. PMID: 16760272
Over the last decade, the concept of targeted biological therapy for the treatment of cancer has emerged. However, a better understanding of these targets and their role in tumor cells...
10.
Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer
Cascone T, Morelli M, Ciardiello F
Ann Oncol . 2006 Apr; 17 Suppl 2:ii46-48. PMID: 16608981
Despite recent developments in the diagnosis and conventional treatment of non small cell lung cancer (NSCLC), the prognosis remains unsatisfactory, with 5-year survival rates of approximately 15% for all stages....